HDAC and MEK inhibition synergistically suppresses HOXC6 and enhances PD-1 blockade efficacy in BRAF<sup>V600E</sup>-mutant microsatellite stable colorectal cancer
Our findings indicate that combining HDAC inhibitor, MEK inhibitor, and PD-1 blockade is a potential strategy for treating BRAF<sup>V600E</sup>-mutant MSS CRC, warranting further investigation in clinical settings.
Authors
- Jinhong Xia
- Jinying Jia
- Zhaoya Gao (ORCID: https://orcid.org/0000-0002-0874-2266)
- Jin Gu (ORCID: https://orcid.org/0000-0002-9650-1963)
- Yang Peng (ORCID: https://orcid.org/0000-0002-0630-9506)
- Mengyuan Shi
- Zhuang Sun (ORCID: https://orcid.org/0000-0002-5159-3753)
- Dengbo Ji (ORCID: https://orcid.org/0000-0002-5164-7344)
- Xin Li (ORCID: https://orcid.org/0000-0001-9024-7522)
- Hanyang Wang (ORCID: https://orcid.org/0009-0002-2275-6987)
- Nan Chen (ORCID: https://orcid.org/0009-0004-3487-1602)
Institutions
- Peking University (CN)
- Peking University Cancer Hospital (CN)
- Peking University Shougang Hospital (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1136/jitc-2024-010460
- Citations
- 8
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 8.36
Funders
- National Natural Science Foundation of China
- Peking University